Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB reduced its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 73.8% during the fourth quarter, Holdings Channel.com reports. The fund owned 516,469 shares of the biopharmaceutical company’s stock after selling 1,452,700 shares during the quarter. Handelsbanken Fonder AB’s holdings in Halozyme Therapeutics were worth $24,692,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of HALO. CWM LLC grew its stake in shares of Halozyme Therapeutics by 77.5% in the 3rd quarter. CWM LLC now owns 1,530 shares of the biopharmaceutical company’s stock worth $88,000 after purchasing an additional 668 shares during the last quarter. Creative Planning boosted its holdings in Halozyme Therapeutics by 25.6% during the third quarter. Creative Planning now owns 46,834 shares of the biopharmaceutical company’s stock worth $2,681,000 after buying an additional 9,543 shares in the last quarter. Raymond James & Associates grew its position in Halozyme Therapeutics by 87.1% in the third quarter. Raymond James & Associates now owns 273,591 shares of the biopharmaceutical company’s stock worth $15,660,000 after buying an additional 127,330 shares during the last quarter. Private Advisor Group LLC grew its position in Halozyme Therapeutics by 6.2% in the third quarter. Private Advisor Group LLC now owns 24,163 shares of the biopharmaceutical company’s stock worth $1,383,000 after buying an additional 1,410 shares during the last quarter. Finally, International Assets Investment Management LLC increased its holdings in shares of Halozyme Therapeutics by 5,623.9% in the third quarter. International Assets Investment Management LLC now owns 36,576 shares of the biopharmaceutical company’s stock valued at $20,940,000 after buying an additional 35,937 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors.

Halozyme Therapeutics Stock Performance

HALO stock opened at $57.44 on Friday. The firm has a 50 day simple moving average of $53.26 and a 200 day simple moving average of $54.58. Halozyme Therapeutics, Inc. has a 52 week low of $36.61 and a 52 week high of $65.53. The stock has a market cap of $7.31 billion, a P/E ratio of 16.75, a P/E/G ratio of 0.44 and a beta of 1.25. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 165.13%. The company had revenue of $298.01 million during the quarter, compared to the consensus estimate of $285.74 million. Research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.72 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

HALO has been the topic of a number of recent research reports. JMP Securities lifted their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a report on Friday, November 1st. Wells Fargo & Company dropped their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Piper Sandler upped their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research note on Friday, January 10th. HC Wainwright lifted their target price on shares of Halozyme Therapeutics from $70.00 to $72.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Benchmark restated a “buy” rating and issued a $75.00 price target on shares of Halozyme Therapeutics in a research report on Thursday. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $62.78.

Insider Buying and Selling

In related news, Director Jeffrey William Henderson sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total value of $281,500.00. Following the completion of the sale, the director now owns 38,611 shares of the company’s stock, valued at approximately $2,173,799.30. The trade was a 11.46 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 2.40% of the stock is owned by corporate insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.